GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NVDA · Jul 26, 2026

NVIDIA CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001045810-26-000075General Corporate
Debt relative to revenue45thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

34.68% · OPTIONAL · VALID

Capex intensity36thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.78% · OPTIONAL · VALID

Operating cash generation25thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

25.02% · OPTIONAL · VALID

Revenue growth75thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

105.85% · CORE · VALID

Inventory pressure75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

32.81% · OPTIONAL · VALID

Gross margin85thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

74.98% · CORE · VALID

Operating margin100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

66.24% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

7.33% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.11% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History25 statesSelf-history eligible
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
10.38%
Current
34.68%
Delta
24.30%
Capex Intensity Increased
Previous
2.15%
Current
2.78%
Delta
0.63%
Cash Generation Decreased
Previous
61.68%
Current
25.02%
Delta
-36.66%
Growth Increased
Previous
85.23%
Current
105.85%
Delta
20.62%
Inventory Pressure Increased
Previous
31.61%
Current
32.81%
Delta
1.21%
Margin Increased
Previous
74.93%
Current
74.98%
Delta
0.04%
Profitability Increased
Previous
65.60%
Current
66.24%
Delta
0.64%
R And D Intensity Decreased
Previous
7.74%
Current
7.33%
Delta
-0.41%
Sbc Intensity Decreased
Previous
2.36%
Current
2.11%
Delta
-0.26%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Oct 26, 2025
Similarity
78%
Compared
9 dimensions
Coverage
100%
Growth 27.9 · Margin 10.0 · Profitability 5.0 · Sbc Intensity 0.0 · Capex Intensity 18.8 · Cash Generation 40.0 · R And D Intensity 0.0 · Inventory Pressure 0.0 · Balance Sheet Leverage 40.0
Oct 29, 2023
Similarity
73%
Compared
8 dimensions
Coverage
89%
Growth 25.0 · Margin 15.0 · Profitability 0.0 · Sbc Intensity 0.0 · Cash Generation 41.7 · R And D Intensity 0.0 · Inventory Pressure 51.9 · Balance Sheet Leverage 21.9
Apr 26, 2026
Similarity
72%
Compared
9 dimensions
Coverage
100%
Growth 11.8 · Margin 0.0 · Profitability 0.0 · Sbc Intensity 0.0 · Capex Intensity 20.3 · Cash Generation 70.0 · R And D Intensity 0.0 · Inventory Pressure 20.0 · Balance Sheet Leverage 35.0
Jul 28, 2024
Similarity
67%
Compared
8 dimensions
Coverage
89%
Growth 0.0 · Margin 8.8 · Profitability 6.3 · Sbc Intensity 0.0 · Cash Generation 68.3 · R And D Intensity 0.0 · Inventory Pressure 50.0 · Balance Sheet Leverage 38.8
Jan 26, 2025
Similarity
64%
Compared
9 dimensions
Coverage
100%
Growth 3.6 · Margin 3.9 · Profitability 5.6 · Sbc Intensity 5.6 · Capex Intensity 1.8 · Cash Generation 63.2 · R And D Intensity 5.6 · Inventory Pressure 75.0 · Balance Sheet Leverage 45.0
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.